genet
divers
swine
influenza
viru
siv
north
america
increas
last
two
decad
howev
major
siv
infect
pig
caus
subtyp
emerg
subtyp
contain
tripl
reassort
intern
gene
trig
cassett
contribut
vastli
gener
antigen
diverg
reassort
virus
hemagglutinin
ha
gene
virus
deriv
differ
season
human
influenza
virus
subtyp
contain
also
exhibit
high
rate
diverg
current
classifi
cluster
emerg
pandem
viru
subsequ
reassort
recent
variant
increas
antigen
variat
siv
combin
ha
gene
allel
trig
cassett
might
contribut
toward
surviv
propag
emerg
siv
variant
pig
establish
antigen
variant
swine
popul
pose
zoonot
threat
transmit
human
current
vaccin
approach
inadequ
counter
antigen
divers
siv
vaccinederiv
protect
immun
typic
strainspecif
vaccin
siv
routin
employ
swine
farm
commerci
vaccin
bival
trival
contain
whole
inactiv
viru
siv
strain
use
vaccin
vari
region
protect
efficaci
depend
strain
preval
area
although
inactiv
vaccin
effect
homolog
strain
limit
protect
offer
heterolog
strain
moreov
inactiv
siv
vaccin
also
associ
develop
vaccineassoci
enhanc
respiratori
diseas
vaerd
happen
vaccin
challeng
strain
belong
subtyp
differ
due
antigen
drift
anoth
weak
current
employ
commerci
inactiv
vaccin
product
administ
intramuscular
rout
induc
adequ
mucos
immun
import
crossprotect
activ
influenza
vaccin
larg
correl
mucos
immun
intranas
administr
live
attenu
siv
vaccin
contain
viru
truncat
protein
modifi
ha
protein
develop
mucos
humor
antibodi
differ
anim
speci
similarli
intranas
inocul
season
trival
inactiv
vaccin
provid
mucos
immun
mice
vaccin
provid
protect
homolog
heterolog
strain
intranas
vaccin
administr
induc
higher
secretori
iga
product
compar
administr
parenter
rout
iga
antibodi
higher
avid
igg
antibodi
readili
access
mucos
viral
antigen
abl
provid
protect
heterolog
strain
furthermor
use
effect
mucos
adjuv
conjunct
intranas
vaccin
administr
could
enhanc
vaccin
effici
poli
c
synthet
doublestrand
rna
demonstr
potent
adjuv
capabl
enhanc
host
innat
immun
respons
intranas
administr
bival
inactiv
influenza
viru
vaccin
along
poli
c
protect
mice
heterolog
strain
studi
evalu
immunogen
protect
efficaci
poli
c
adjuv
bival
inactiv
siv
vaccin
pav
commerci
pig
intranas
administr
pav
pig
induc
iga
antibodi
respons
respiratori
tract
provid
protect
challeng
antigen
variant
heterolog
siv
madindarbi
canin
kidney
mdck
cell
cell
grown
dmem
supplement
fb
antibiot
mm
lglutamin
newli
establish
spontan
immort
cell
line
deriv
distal
trachea
proxim
lung
tissu
weekold
pig
cell
express
avian
mammalian
influenza
viru
receptor
support
replic
swine
avian
humanorigin
influenza
virus
unpublish
result
swine
influenza
virus
cluster
ii
use
prepar
experiment
vaccin
cell
viru
obtain
dr
ja
richt
depart
diagnost
medicinepathobiolog
kansa
state
univers
manhattan
ks
prepar
vaccin
stock
cell
infect
virus
presenc
g
tolylsulfonyl
phenylalanyl
chloromethyl
ketonetr
tpck
trypsin
h
virusinfect
cultur
frozen
thaw
three
time
cellular
debri
clear
centrifug
supernat
inactiv
uv
irradi
use
uv
lamp
nm
min
el
seri
entela
upland
ca
viru
inactiv
confirm
inabl
virus
replic
mdck
cell
swinenorth
use
challeng
virus
ha
amino
acid
homolog
challeng
viru
stock
prepar
mdck
cell
describ
previous
commerci
vaccin
contain
kill
swine
virus
adjuv
also
includ
studi
pneumostar
siv
complet
novarti
anim
health
us
inc
larchwood
ia
twentyeight
threeweekold
wean
pig
obtain
commerci
herd
pig
deriv
sow
immun
maxivac
excel
r
intervet
swine
influenza
vaccin
pig
acclimat
day
vaccin
inocul
mainten
pig
experiment
procedur
conduct
accord
guidelin
institut
laboratori
anim
care
use
committe
south
dakota
state
univers
group
threeweekold
commerci
influenza
antibodyposit
pig
inocul
intranas
uvinactiv
vaccin
contain
tcid
per
pig
poli
c
g
per
pig
pav
commerci
vaccin
cv
manufactur
recommend
dose
twice
week
interv
previou
studi
poli
c
gpig
shown
enhanc
immunogen
foot
mouth
diseas
fmdv
multiepitop
vaccin
poli
c
adjuv
vaccin
provid
complet
protect
virul
fmdv
challeng
pig
hous
separ
isol
unit
time
booster
vaccin
three
week
immun
challeng
collect
blood
examin
hi
titer
three
week
immun
pig
challeng
antigen
variant
heterolog
virus
tcid
per
pig
intranas
rout
tabl
pig
monitor
daili
clinic
sign
challeng
euthan
nasal
swab
collect
day
postchalleng
dpc
viru
titrat
mdck
cell
dpc
pig
euthan
pentobarbit
administr
lung
examin
gross
pneumon
lesion
lung
lysat
prepar
viru
quantif
gross
lung
lesion
evalu
describ
previous
total
percent
consolid
area
purpl
color
calcul
base
weight
proport
lobe
total
lung
volum
score
assign
base
upon
percentag
virusaffect
lesion
lung
lobe
wv
homogen
individu
lung
lobe
left
cranial
left
caudal
right
cranial
right
middl
right
caudal
accessori
lobe
prepar
dmem
antibiot
use
tissu
homogen
omni
homogen
glh
omni
tip
tm
plastic
gener
probe
omni
intern
debri
remov
centrifug
min
g
supernat
collect
filter
filter
serial
tenfold
dilut
nasal
swab
lung
homogen
prepar
dmem
supplement
g
tpck
trypsinml
mdck
cell
cultur
tissuecultur
plate
inocul
dilut
examin
cytopath
effect
h
incub
c
viru
titer
calcul
reed
muench
method
crossreact
hi
antibodi
sera
pav
cvimmun
pig
detect
standard
hi
assay
manual
blood
collect
time
booster
vaccin
challeng
hi
antibodi
detect
challeng
virus
challeng
virusspecif
iga
igg
antibodi
lung
lysat
igg
serum
measur
elisa
describ
previous
modif
briefli
maxisorp
plate
thermo
scientif
coat
overnight
ha
unit
rt
plate
block
h
rt
l
fat
free
milk
phosphat
buffer
salin
contain
tween
pbst
tri
nacl
tween
block
buffer
wash
four
time
pbst
serum
sampl
dilut
lung
lysat
sampl
dilut
block
buffer
ad
lwell
duplic
plate
incub
h
rt
wash
four
time
plate
incub
hrp
label
antiporcin
iga
bethyl
lab
igg
antibodi
kpl
h
wash
plate
develop
use
abt
substrat
optic
densiti
od
measur
nm
molecular
devic
spectramax
plu
lung
gross
lesion
log
hi
titer
log
viru
titer
nasal
swab
lung
elisa
od
valu
immun
nonimmun
pig
compar
use
oneway
anova
follow
tukey
test
p
consid
statist
signific
measur
serum
hi
antibodi
challeng
virus
dpv
pig
nonvaccin
group
minim
hi
antibodi
eiher
antigen
dpv
pig
cvinocul
group
mean
specif
hi
titer
dayspostvaccin
dpv
respect
wherea
pav
induc
specif
titer
dpv
dpv
immun
pig
fig
virusspecif
mean
hi
titer
shown
fig
cv
pav
induc
hi
antibodi
hi
titer
slightli
higher
cvimmun
pig
dpv
compar
pavimmun
pig
wherea
dpv
hi
titer
higher
pav
group
fig
also
determin
igg
antibodi
respons
serum
immun
pig
challeng
dpc
low
level
igg
antibodi
detect
nonvaccin
nonvaccin
challeng
group
serum
igg
level
slightli
higher
cvimmun
group
dpc
dpc
pav
group
howev
increas
signific
p
fig
b
main
goal
studi
examin
poli
c
adjuv
enhanc
protect
immun
inactiv
swine
influenza
vaccin
respiratori
tract
therefor
studi
pig
immun
nasal
rout
examin
vaccineinduc
mucos
antibodi
respons
respiratori
tract
examin
igg
iga
antibodi
lung
lysat
pig
dpc
fig
low
level
igg
antibodi
observ
nonvaccin
group
igg
antibodi
pav
immun
pig
slightli
higher
cvimmun
pig
wherea
igg
antibodi
strain
less
cvimmun
group
fig
infect
nonvaccin
pig
induc
iga
antibodi
respons
lung
iga
antibodi
respons
lung
pav
immun
pig
higher
iga
level
lung
lysat
cv
immun
pig
fig
result
indic
intranas
immun
pav
induc
mucos
antibodi
respons
assess
protect
efficaci
pav
cv
compar
reduct
lung
lesion
viru
shed
nasal
secret
challeng
viru
titer
lung
pig
infect
nonvaccin
challeng
pig
produc
extens
lung
lesion
fig
immun
pig
either
pav
cv
less
lung
lesion
compar
nonimmun
challeng
pig
mean
lung
lesion
significantli
less
p
pavand
cvimmun
pig
compar
nonimmun
challeng
pig
lung
lesion
also
less
pavimmun
pig
cvimmun
challeng
pig
fig
likewis
mean
lung
lesion
pavimmun
challeng
pig
less
p
nonimmun
challeng
pig
lung
lesion
also
consider
less
pavimmun
pig
lung
lesion
cvimmun
challeng
pig
fig
data
indic
pav
provid
protect
challeng
antigen
variant
heterolog
swine
influenza
virus
next
determin
challeng
viru
shed
examin
viru
titer
nasal
swab
collect
dpc
titrat
mdck
cell
viru
shed
data
shown
fig
challeng
virus
detect
nonchalleng
pig
data
shown
dpc
viru
shed
nasal
secret
significantli
lower
p
cv
pav
immun
pig
challeng
compar
nonimmun
challeng
pig
importantli
pav
immun
pig
challeng
heterolog
siv
show
significantli
less
p
viru
shed
dpc
compar
nonimmun
challeng
pig
fig
dpc
essenti
similar
trend
observ
pav
immun
pig
shed
significantli
less
p
challeng
virus
compar
nonimmun
challeng
pig
fig
also
determin
challeng
viru
titer
lung
immun
nonimmun
challeng
pig
collect
dpc
titrat
mdck
cell
unvaccin
challeng
group
replic
high
titer
lung
fig
viru
titer
lung
pav
immun
pig
significantli
less
p
nonimmun
challeng
pig
fig
titer
challeng
virus
also
lower
cv
immun
pig
compar
nonimmun
pig
fig
studi
evalu
immunogen
crossprotect
efficaci
pav
administ
intranas
matern
antibodi
posit
convent
pig
intranas
administr
pav
induc
challeng
virusspecif
hi
igg
antibodi
serum
iga
antibodi
respiratori
tract
provid
protect
challeng
antigen
variant
heterolog
siv
vaccin
administ
intranas
rout
induc
mucos
system
immun
respons
administr
parenter
rout
elicit
system
immun
respons
poli
c
agonist
use
adjuv
shown
enhanc
immun
respons
influenza
previou
studi
mice
demonstr
intranas
administr
poli
c
adjuv
vaccin
induc
increas
iga
titer
nasal
wash
provid
protect
homolog
heterolog
viru
challeng
similar
find
report
recent
human
ampligen
synthet
poli
c
use
adjuv
along
flumist
vaccin
similarli
studi
intranas
administr
pav
provid
protect
heterolog
siv
pig
also
observ
higher
iga
titer
lung
pav
vaccin
pig
compar
cv
vaccin
pig
therefor
observ
previou
studi
mice
human
higher
iga
titer
lung
pav
vaccin
pig
may
involv
induc
crossprotect
immun
antigen
variant
heterolog
siv
addit
boost
mucos
iga
respons
poli
c
also
enhanc
cellmedi
immun
use
vaccin
adjuv
poli
c
shown
enhanc
activ
respiratori
dendrit
cell
help
migrat
effector
memori
cell
intranas
administr
poli
c
mice
caus
cell
prolifer
recruit
cell
airway
current
studi
small
increas
serum
lung
igg
titer
vaccinatedchalleng
pig
also
level
crossreact
hi
antibodi
low
pav
cvimmun
pig
although
examin
studi
crossprotect
observ
studi
indic
addit
crossreact
hi
mucos
antibodi
crossreact
cell
may
also
play
role
provid
protect
antigen
variant
heterolog
siv
pavimmun
pig
previous
inactiv
siv
vaccin
shown
induc
crossreact
cell
respons
immun
pig
mean
percent
gross
lesion
score
significantli
decreas
pig
receiv
pav
challeng
either
homolog
heterolog
strain
compar
nv
pig
previous
vaerd
report
pig
vaccin
inactiv
influenza
vaccin
follow
challeng
heterolog
viru
although
mechan
vaerd
poorli
defin
recent
research
suggest
one
contribut
factor
could
product
crossreact
igg
nonneutr
epitop
similar
inactiv
swine
influenza
vaccin
induc
vaerd
intranas
administr
uv
inactiv
sever
acut
respiratori
syndrom
sar
vaccin
mice
induc
extens
eosinophil
infiltr
lung
could
enhanc
respiratori
diseas
also
immun
respons
skew
toward
cell
activ
result
product
excess
antibodi
howev
administr
combin
tlr
agonist
includ
poli
c
along
uv
inactiv
sar
vaccin
reduc
eosinophil
infiltr
shift
immun
respons
cell
mediat
immun
produc
high
neutral
antibodi
titer
present
studi
use
poli
c
adjuv
uvinactiv
siv
vaccin
observ
signific
protect
challeng
antigen
variant
heterolog
siv
without
evid
vaerd
collect
find
previou
find
sar
vaccin
studi
suggest
poli
c
protect
effect
vaerd
transmiss
swine
influenza
pig
human
occur
aerosol
viru
mostli
shed
nasal
discharg
surround
environ
effici
vaccin
could
prevent
viru
replic
airway
thu
reduc
viru
shed
posit
correl
viru
shed
nasal
secret
possibl
previous
uninfect
pig
get
infect
aerosol
therefor
pertin
even
vaccin
yield
partial
protect
could
slow
rate
influenza
transmiss
pig
receiv
pav
shed
significantli
less
viru
nasal
discharg
dpc
infect
antigen
variant
heterolog
strain
addit
viru
load
lung
dpc
significantli
lower
pav
immun
group
compar
nv
challeng
find
suggest
pav
vaccin
confer
effect
protect
homolog
heterolog
strain
previou
research
demonstr
poli
c
reduc
replic
chikungunya
viru
vitro
pretreat
mice
poli
c
provid
signific
protect
sar
influenza
infect
poli
c
also
effect
adjuv
foot
mouth
diseas
vaccin
pig
influenza
viru
vaccin
studi
chicken
human
efficaci
safeti
ampligen
synthet
poli
c
test
clinic
experi
preliminari
find
suggest
pavimmun
pig
protect
influenza
challeng
use
poli
c
adjuv
inactiv
vaccin
caus
vaerd
pig
howev
protect
incomplet
therefor
addit
studi
requir
optim
vaccin
poli
c
dose
enhanc
crossprotect
efficaci
pav
use
field
situat
